Last reviewed · How we verify

Аrgon-oxygen breathing mixture

Negovsky Reanimatology Research Institute · Phase 3 active Small molecule

An argon-oxygen breathing mixture enhances tissue oxygenation and reduces hypoxia by delivering a gas combination with optimized oxygen availability and inert gas properties.

An argon-oxygen breathing mixture enhances tissue oxygenation and reduces hypoxia by delivering a gas combination with optimized oxygen availability and inert gas properties. Used for Resuscitation and post-resuscitation care, Hypoxic-ischemic encephalopathy.

At a glance

Generic nameАrgon-oxygen breathing mixture
SponsorNegovsky Reanimatology Research Institute
Drug classMedical gas mixture
ModalitySmall molecule
Therapeutic areaCritical Care / Resuscitation
PhasePhase 3

Mechanism of action

Argon is a noble gas with potential neuroprotective properties, while the oxygen component ensures adequate tissue perfusion. The mixture may work by reducing oxidative stress, improving microcirculation, and providing cytoprotective effects during ischemic or hypoxic conditions. This combination is investigated for resuscitation and critical care applications where rapid reoxygenation and neuroprotection are needed.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: